#USA #New York #Class Action #Faruqi & Faruqi #ARS Pharmaceuticals

Investment Alert: ARS Pharmaceuticals Faces Class Action Lawsuit

Faruqi & Faruqi, LLP, a well-respected national securities law firm, reminds investors regarding upcoming critical deadlines related to ARS Pharmaceuticals Inc. (NASDAQ: SPRY). If you purchased or acquired securities between March 9, 2026, and June 24, 2026, you may need to take action ahead of the class action lawsuit deadline set for October 5, 2026.

The firm is currently investigating potential claims regarding significant alleged misrepresentations and omissions made by ARS Pharmaceuticals and its executives. The complaint asserts that the company provided unverified positive statements to the public while simultaneously concealing crucial, unfavorable information regarding the timeline for expanding insurance coverage for its product, Neffy.

On June 24, 2026, ARS Pharmaceuticals released shocking news after market hours, detailing that no new additions or coverage decisions were forthcoming from CVS Caremark for Neffy as expected. This announcement led to a staggering decline in ARS's share price by $2.52—or approximately 23.9%—the following day, closing at $8.02. The drastic drop in stock price was attributed to the unexpected public revelation of these misleading statements and practices,

Faruqi & Faruqi’s partner, James (Josh) Wilson, is actively encouraging investors who have suffered losses from ARS’s stock decline to pursue their legal rights. Participants in the class action risk missed opportunities if they do not act on time. Potential claimants can get in touch with Wilson directly by calling 877-247-4292 or 212-983-9330 (Ext. 1310).

Understanding Your Rights

In the context of a securities class action lawsuit, the lead plaintiff is typically the individual with the most substantial financial interest in the outcome of the lawsuit. This person helps to oversee the litigation and directs the legal strategy. However, it’s essential to note that eligibility for participation in this suit is widespread. Even if someone does not wish to be the lead plaintiff, they can still share in any potential recovery the lawsuit secures for the class as a whole.

Investors who bought ARS stock during the designated class period are encouraged to assess their losses meticulously and preserve all relevant documents, including trade confirmations and account statements. These records might prove crucial for any legal proceedings.

Why It Matters

The importance of filing a claim cannot be stressed enough. The firm has been representing investors for decades, recovering hundreds of millions of dollars for clients since its establishment. The knowledge and resources available through Faruqi & Faruqi position investors to fight back against misleading corporate practices that harm shareholders.

James (Josh) Wilson assures that any discussions initiated with their firm will maintain strict confidentiality, and they offer no-cost consultations for potential clients seeking guidance.

Final Thoughts

As the deadline approaches, it is imperative for investors in ARS Pharmaceuticals to weigh their options carefully. Those who want to emerge from this situation with their rights preserved need to act promptly and seek advice from seasoned attorneys. The firm encourages anyone with information related to ARS Pharmaceuticals’ practices—whistleblowers, former employees, and shareholders alike—to reach out and share their insights.

For more information regarding the class action related to ARS Pharmaceuticals, visit www.faruqilaw.com/SPRY or call Faruqi & Faruqi directly. Keeping track of these developments will be vital as this case unfolds.

• ---

Legal Advertisement. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP. Prior results do not guarantee or predict a similar outcome with respect to any future matter.